# HIV Clinical Decision Support Report

Generated: 2025-12-26T04:01:55.762824

## Executive Summary

- **TOP VACCINE CANDIDATE: TPQDLNTML from Gag (priority score: 0.970)**
- **MDR ALERT: 2489 high-risk sequences detected (34.8% of screened population)**
- **DRUG TARGETS: 247 high-druggability Tat targets identified for host-directed therapy development**

## Priority Action Items

### [HIGH] Resistance Monitoring
**Action**: Implement L63P/L90M screening in clinical genotyping

**Rationale**: 79.5% of MDR cases carry L63P mutation

### [MEDIUM] Vaccine Development
**Action**: Advance TPQDLNTML to preclinical

**Rationale**: Highest stability score + population coverage

### [RESEARCH] Drug Development
**Action**: Screen 20 kinase inhibitors for Tat disruption

**Rationale**: Host-directed approach avoids resistance

## Vaccine Development

### Top Candidates

| Epitope | Protein | Priority Score | Stability | Coverage |
|---------|---------|----------------|-----------|----------|
| TPQDLNTML | Gag | 0.970 | 173.7 | 0.95 |
| YFPDWQNYT | Nef | 0.878 | 133.9 | 0.95 |
| QVPLRPMTYK | Nef | 0.878 | 133.9 | 0.95 |
| RAIEAQQHL | Env | 0.864 | 121.0 | 0.95 |
| AAVDLSHFL | Nef | 0.848 | 133.9 | 0.95 |
| YPLTFGWCF | Nef | 0.848 | 133.9 | 0.95 |
| RPQVPLRPM | Nef | 0.846 | 119.8 | 0.95 |
| RYPLTFGW | Nef | 0.830 | 112.7 | 0.95 |
| TAFTIPSI | Pol | 0.825 | 104.3 | 0.95 |
| RLRPGGKKKY | Gag | 0.825 | 104.2 | 0.95 |

## Resistance Monitoring

- Total screened: 7154
- High risk: 2489
- Mean risk score: 0.513

### MDR Signature Mutations

| Mutation | Frequency |
|----------|----------|
| I54V | 4627 |
| L10I | 1640 |
| L63P | 1533 |
| M36I | 1429 |
| I93L | 1419 |
| L90M | 970 |
| A71V | 828 |
| L33F | 734 |
| V82A | 514 |
| M46I | 2 |

## Host-Directed Therapy Targets

### Tat-Interacting Druggable Proteins

| Protein | Family | Druggability |
|---------|--------|-------------|
| 1-phosphatidylinositol 3-phosphate 5-kinase isofor | kinase | high |
| urokinase-type plasminogen activator isoform 1 pre | kinase | high |
| vascular endothelial growth factor receptor 1 isof | receptor | high |
| vascular endothelial growth factor receptor 2 prec | receptor | high |
| TNF receptor-associated factor 3 isoform 1 | receptor | high |
| TNF receptor-associated factor 4 | receptor | high |
| bone morphogenetic protein receptor type-1A precur | receptor | high |
| bone morphogenetic protein receptor type-1B isofor | receptor | high |
| bone morphogenetic protein receptor type-2 precurs | receptor | high |
| cAMP-dependent protein kinase catalytic subunit al | kinase | high |
| cAMP-dependent protein kinase catalytic subunit be | kinase | high |
| cAMP-dependent protein kinase catalytic subunit ga | kinase | high |
| cAMP-dependent protein kinase type I-alpha regulat | kinase | high |
| cAMP-dependent protein kinase type I-beta regulato | kinase | high |
| cAMP-dependent protein kinase type II-alpha regula | kinase | high |

### Recommendations

- Consider repurposing existing kinase inhibitors - 20 kinase targets identified
- Receptor-based therapies promising - 20 receptor targets identified
- Host-directed therapy via Tat targets avoids viral resistance evolution
